Trials
Osimertinib Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
What is ADAURA?
Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer is being studied in this trial
What is NeoADAURA?
First and only EGFR TKI ALMOST indicated for locally advanced, unresectable stage III EGFRm NSCLC
What is 2024?
TAGRISSO tablets come in this strength(s)
What is 40 and 80 mg?
TAGRISSO is still conducting trials in this space and will hopefully be included in the NCCN Guidelines shortly
What is neoadjuvant and stage IA
the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy is an indication that was approved based on this trial
What is AURA3?
This patient population is eligible for first-line treatment with TAGRISSO
What is metastatic/ what is locally advanced and metastatic?
FDA approval of TAGRISSO + CT (pem/plat) for 1L locally advanced/metastatic EGFRm NSCLC
What is 2024?
Tagrisso mechanism of action
What is a kinase inhibitor of the epidermal growth factor receptor (EGFR), which binds irreversibly to certain mutant forms of EGFR (T790M, L858R, and exon 19 deletions)?
To help guide treatment selection of Systemic Therapy Following Surgical Resection in patients with stages IB–IIIA, IIIB [T3,N2], NCCN Guidelines recommends testing for following biomarkers
What is PD-L1 status, EGFR mutations, and ALK rearrangements?
Patients with unresectable EGFRm stage III NSCLC without progression during or after chemoradiotherapy received osimertinib or placebo in this trial
What is LAURA?
Patients who have the following EGFR mutations are eligible for treatment with TAGRISSO
What are EGFR exon 19 deletions or exon 21 L858R mutations?
FDA approval with breakthrough therapy designation in resectable EGFRm NSCLC
What is 2020?
The top 3 oncogenic drivers in NSCLC
EGFR, KRAS, MET
For patients with completely resected stage IB–IIIA or stage IIIB (T3, N2) NSCLC and positive for EGFR (exon 19 deletion, exon 21 L858R) mutations who received previous adjuvant chemotherapy or are ineligible to receive platinum-based chemotherapy, osimertinib is recommended for this long
What is 3 years?
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer
What is FLAURA2?
TAGRISSO is indicated for the treatment of adult patients with metastatic NSCLC whose disease has progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy if they have this mutation
What is EGFR T790M?
FDA approval with breakthrough therapy designation in 1L EGFRm mNSCLC
What is 2018?
The epidermal growth factor receptor (EGFR) gene was first discovered in non-small cell lung cancer (NSCLC) in ...
What is 2004?
Systemic therapy is recommended as 1L therapy in advanced/metastatic patients with the following mutations
What is KRAS G12C mutation and ERBB2 (HER2) mutation?
FUN FACT: Until recently, EGFR exon 20 insertion mutation was also on this list until Amivantamab-vmjw + carboplatin/ pemetrexed was approved!
Patients with previously untreated, EGFR mutation-positive (exon 19 deletion or L858R) metastatic NSCLC received either osimertinib or gefitinib/erlotinib in this trial
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
What is ADAURA2?
FDA approval with breakthrough therapy designation in 2L T790M EGFRm mNSCLC
What is 2015?
Name an AZ drug in each category:
ADC, TDR, IO
ADC (Antibody-drug conjugates): Dato-Dxd
TDR (Tumour drivers and resistance): Tagrisso
IO (Immuno-Oncology): Imfinzi
Test for these biomarkers in advanced, metastatic NSCLC (10)
EGFR mutation (category 1), ALK (category 1), KRAS, ROS1, BRAF, NTRK1/2/3, METex14 skipping, RET, ERBB2 (HER2), and PD-L1 (category 1)